Parathyroid Hormone–related Peptide (PTHrP)-dependent and -independent Effects of Transforming Growth Factor β (TGF-β) on  Endochondral Bone Formation by Serra, Rosa et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/99/05/783/12 $2.00
The Journal of Cell Biology, Volume 145, Number 4, May 17, 1999 783Ð794
http://www.jcb.org 783
 
Parathyroid Hormone–related Peptide (PTHrP)-dependent and
 
-independent Effects
 
 
 
of Transforming Growth
 
 
 
Factor
 
 
 
b 
 
(TGF-
 
b
 
) on 
Endochondral Bone Formation
 
Rosa Serra,* Andrew Karaplis,
 
‡
 
 and Philip Sohn*
 
*Department of Cell Biology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232; and 
 
‡
 
Department of 
Medicine, Division of Endocrinology, Lady Davis Institute for Medical Research, McGill University, Montreal, Quebec H3T 
1E2, Canada
 
Abstract. 
 
Previously, we showed that expression of a 
dominant-negative form of the transforming growth 
 
factor 
 
b
 
 (TGF-
 
b
 
) type II receptor in skeletal tissue re-
sulted in increased hypertrophic differentiation in 
growth plate and articular chondrocytes, suggesting a 
role for TGF-
 
b
 
 in limiting terminal differentiation in 
vivo. Parathyroid hormoneÐrelated peptide (PTHrP) 
has also been demonstrated to regulate chondrocyte 
differentiation in vivo. Mice with targeted deletion of 
the PTHrP gene demonstrate increased endochondral 
bone formation, and misexpression of PTHrP in carti-
lage results in delayed bone formation due to slowed 
conversion of proliferative chondrocytes into hyper-
trophic chondrocytes. Since the development of skele-
tal elements requires the coordination of signals from 
several sources, this report tests the hypothesis that 
TGF-
 
b
 
 and PTHrP act in a common signal cascade to 
regulate endochondral bone formation. Mouse embry-
onic metatarsal bone rudiments grown in organ culture 
were used to demonstrate that TGF-
 
b
 
 inhibits several 
stages of endochondral bone formation, including 
chondrocyte proliferation, hypertrophic differentiation, 
and matrix mineralization. Treatment with TGF-
 
b
 
1 
also stimulated the expression of PTHrP mRNA. 
PTHrP added to cultures inhibited hypertrophic differ-
entiation and matrix mineralization but did not affect 
cell proliferation. Furthermore, terminal differentiation 
was not inhibited by TGF-
 
b
 
 in metatarsal rudiments 
from PTHrP-null embryos; however, growth and ma-
trix mineralization were still inhibited. The data sup-
port the model that TGF-
 
b
 
 acts upstream of PTHrP to 
regulate the rate of hypertrophic differentiation and 
suggest that TGF-
 
b
 
 has both PTHrP-dependent and 
PTHrP-independent effects on endochondral bone for-
mation.
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T
 
HE
 
 rate of cartilage differentiation must be carefully
regulated so that bones attain the proper shape and
length. Early in skeletal development, mesenchy-
mal cells condense and differentiate into chondroblasts,
which form the initial shape of the bone rudiment. Chon-
droblasts then undergo a complex program of prolifera-
tion, maturation, and hypertrophy. Hypertrophic cartilage
is then replaced with bone. Endochondral bone formation
is complex and requires the coordination of signals from
several factors and multiple cell types (reviewed in Can-
cedda et al., 1995; Erlebacher et al., 1995). Chondrocyte
differentiation is regulated by factors synthesized by both
chondrocytes and cells in the perichondrium, the layer of
mesenchyme that surrounds the cartilage rudiment.
 
Parathyroid hormone–related peptide (PTHrP)
 
1
 
 was
first identified as a factor associated with humoral hyper-
calcemia of malignancy (Broadus and Stewart, 1994).
PTHrP is expressed in a wide variety of adult and embry-
onic cell types, including osteoblasts and chondrocytes
(Broadus and Stewart, 1994; Suva et al., 1987; Lee et al.,
1995). During the development of endochondral bones,
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PTHrP is expressed in periarticular chondrocytes and
resting and maturing chondrocytes of the growth plate.
PTHrP signals through the G protein–coupled parathyroid
hormone (PTH) receptor, which is also expressed in a
wide range of adult and embryonic cells, including chon-
drocytes at the transition between the zones of prolifera-
tion and hypertrophy (Lee et al., 1993, 1995). The im-
portance of PTHrP in endochondral bone formation is
demonstrated in mice homozygous for a targeted disrup-
tion of the PTHrP gene (Karaplis et al., 1994; Amizuka et
al., 1994, 1996). PTHrP-null mice demonstrate increased
endochondral bone formation. The epiphyses demonstrate
diminished resting and proliferating zones and accelerated
chondrocyte maturation, apoptosis, and replacement with
bone. Mice with targeted deletion of the PTH receptor
demonstrate a similar phenotype (Lanske et al., 1996).
Misexpression of PTHrP in cartilage with the promoter
from the type II collagen gene results in accumulation of
prehypertrophic chondrocytes and inhibition of apoptosis
in late stage hypertrophic chondrocytes (Weir et al., 1996;
Amling et al., 1997). The Jansen type chondrodysplasia in
humans, which is also characterized by a delay in endo-
chondral maturation, has been attributed to a mutation in
the PTH receptor gene that results in a constitutively ac-
tive protein (Schipani et al., 1995). Transgenic mice that
express this mutation demonstrate slowed conversion of
proliferating chondrocytes into hypertrophic chondrocytes
(Schipani et al., 1997). Recently, it was proposed that In-
dian hedgehog (Ihh) and PTHrP form a negative feedback
loop that provides a mechanism for chondrocytes to sense
and regulate their rate of differentiation (Vortkamp et al.,
1996; Lanske et al., 1996; Wallis, 1996). Vertebrate hedge-
hog (Hh) proteins are a family of secreted molecules that
are important regulators of embryonic patterning (Ham-
merschmidt et al., 1997) related to the 
 
Drosophila
 
 seg-
ment polarity gene, 
 
Hh 
 
(Nusslein-Volhard and Wieschaus,
1980). Ihh is expressed in the developing cartilage rudi-
ments, in a population of cells that are committed to be-
come hypertrophic (Bitgood and McMahon, 1995; Vort-
kamp et al., 1996). Misexpression of Ihh in chick limb
cartilage rudiments resulted in inhibition of chondrocyte
differentiation and stimulation of PTHrP mRNA expres-
sion. Furthermore, PTHrP was required for the inhibitory
activities of Hh (Vortkamp et al., 1996; Lanske et al.,
1996).
Members of the TGF-
 
b 
 
superfamily are secreted signal-
ing molecules that regulate many aspects of growth and
differentiation (reviewed in Massague et al., 1990; Moses,
1990; Moses and Serra, 1996). This family includes several
TGF-
 
b
 
 isoforms, the activin and inhibins, growth and dif-
ferentiation factors (GDFs), and the bone morphogenetic
proteins (BMPs), which were first identified by their abil-
ity to induce ectopic bone formation when injected into in-
tramuscular sites. TGF-
 
b
 
1, 2, and 3 mRNA are synthe-
sized in the mouse perichondrium and periosteum from
13.5 d post coitum (p.c.) until after birth (Sandberg et al.,
1988; Pelton et al., 1990a; Gatherer et al., 1990; Millan
et al., 1991). TGF-
 
b
 
 alters chondrocyte differentiation in
vitro and has varying effects depending on the status of the
cells (reviewed in Moses and Serra, 1996). TGF-
 
b
 
 pro-
motes chondrogenesis in cultures of early undifferentiated
mesenchyme (Kulyk et al., 1989; Leonard et al., 1991; Den-
 
ker et al., 1994) but inhibits terminal chondrocyte differen-
tiation in high density chondrocyte pellet cultures or organ
cultures (Kato et al., 1988; Ballock et al., 1993; Tschan et
al., 1993; Bohme et al., 1995; Dieudonne et al., 1994).
Previously, we generated transgenic mice that express a
dominant-negative mutation of the TGF-
 
b
 
 type II recep-
tor (DNIIR) in the periosteum, perichondrium, articular
cartilage, synovium, and the lower hypertrophic zone of
the growth plate (Serra et al., 1997). Transgenic mice dem-
onstrated increased terminal differentiation and persistent
expression of Ihh in growth plate chondrocytes, suggesting
that TGF-
 
b
 
 regulates hypertrophic differentiation in vivo.
Since Ihh normally acts as an inhibitor of chondrocyte dif-
ferentiation, it was proposed that TGF-
 
b
 
 was required for
Ihh-mediated inhibition. This report tests the hypothesis
that TGF-
 
b
 
 and PTHrP act in a common signaling cascade
to regulate chondrocyte differentiation and demonstrates
that TGF-
 
b
 
 has both PTHrP-dependent and PTHrP-inde-
pendent effects on endochondral bone formation.
 
Materials and Methods
 
Embryonic Metatarsal Rudiment Organ Cultures
 
Metatarsal rudiments were isolated from 15.5 d p.c. ICR/B6D2 mouse em-
bryos or embryos from crosses of PTHrP
 
1
 
/
 
2
 
 mice (Karaplis et al., 1994)
and were used as noted. Noon on the day of the vaginal plug is 0.5 d p.c.
The three central metatarsal rudiments were cultured in each well of a 24-
well plate in 1 ml of chemically defined medium containing 
 
a
 
-MEM (cat.
no. 12000-063; GIBCO BRL) supplemented with 0.05 mg/ml ascorbic acid
(Sigma Chemical Co.), 0.3 mg/ml 
 
L
 
-glutamine (Sigma Chemical Co.), 0.05
mg/ml gentamicin 90, 1 mM 
 
b
 
-glycerophosphate (Sigma Chemical Co.),
and 0.2% endotoxin-free fraction V BSA (Sigma Chemical Co.) as previ-
ously described (Dieudonne et al., 1994). Explants were grown at 37
 
8
 
C in
a humidified 5% CO
 
2
 
 incubator. TGF-
 
b
 
1 (1 or 10 ng/ml) in 4 mM HCl
(R&D Systems) or PTHrP (1–34) in 10 mM acetic acid containing 1% BSA
(Bachem) at varying concentration was added to cultures 12–16 h after
dissection. Medium was changed on the third day of culture. Cultures
were observed and photographed with an Olympus SZH10 dissecting mi-
croscope at 24 h, 3 d, and 5 d of treatment. The length of metatarsals was
calculated by measuring the length of rudiment from photographs taken
on the dissecting microscope and dividing by the magnification factor
(usually 
 
3
 
5). The length of several bone rudiments (at least three for each
condition) was calculated, and the data are shown as the mean 
 
6
 
 SD.
 
Histology
 
Metatarsal rudiments were fixed overnight at 4
 
8
 
C in fresh 4% paraformal-
dehyde and then decalcified 2 h to overnight at 4
 
8
 
C in 1 mM Tris, pH 7.5,
10% EDTA tetrasodium salt, 7.5% polyvinyl pyrolidone, and 1 
 
m
 
l/ml di-
ethyl pyrocarbonate (DEPC). The explants were dehydrated through a
series of ethanols and xylene and then embedded in paraffin and cut into
5-
 
m
 
m sections. Sections were stained with hematoxylin and eosin as noted
using standard procedures.
 
Bromo Deoxyuridine Labeling
 
Metatarsal rudiments were treated with 10 
 
m
 
M bromo deoxyuridine
(BrdU; Boehringer Mannheim) for 2.5 h. Metatarsals were then washed
twice in PBS at 37
 
8
 
C, fixed in paraformaldehyde at 4
 
8
 
C overnight, embed-
ded in paraffin, and cut into 5-
 
m
 
m sections. Sections were deparaffinized,
denatured in 2 N HCl for 20 min at 37
 
8
 
C, and neutralized in 1% boric acid/
0.285% sodium borate, pH 7.6. Next, the sections were treated with 0.005
mg trypsin/ml 0.05 M Tris, pH 7.6, for 3 min at 37
 
8
 
C and washed three
times in PBS. Immunostaining was then performed using components and
directions from the Vectastain Elite staining kit (Vector Laboratories). A
rat mAb directed to BrdU (Harlan) was used as the primary antibody at a
1:200 dilution. Cy3-conjugated avidin (Vector Laboratories) was substi-
tuted for the avidin-biotin-peroxidase complex. Excess Cy3-conjugated
avidin was removed from the sections by washing three times for 10 min 
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each in PBS at room temperature, and the sections were immediately
mounted with Aquapoly mount (Poly Sciences). Fluorescence was ob-
served and imaged using a Zeiss Axiophot microscope and a Princeton In-
struments CCD camera with Sellomics imaging software.
 
Immunohistochemistry
 
Immunohistochemical staining of type X collagen was performed using
polyclonal antibodies to mouse type X collagen (a generous gift from
Bjorn Olsen, Harvard Medical School, Boston, MA). Sections were de-
waxed, rehydrated, and incubated with 1 mg/ml hyaluronidase (Sigma
Chemical Co.) in PBS at 37
 
8
 
C for 30 min. Immunohistochemistry was then
performed following the directions supplied with the Vectastain Elite im-
munoperoxidase staining kit (Vector Laboratories). The color reaction
was performed using the DAB substrate kit, also from Vector Laborato-
ries. Sections were very lightly counterstained with toluidine blue, and
photographs were taken under bright field illumination with a Zeiss Axio-
phot microscope. The percentage of the bone rudiment stained for type X
collagen was calculated as follows:
This measurement takes into account changes in the total length of the
bone rudiment.
Immunofluorescent staining for the TGF-
 
b
 
 type I and type II receptors
was performed using polyclonal antibodies obtained from Santa Cruz Bio-
technology (type I, cat. no. sc 398; type II, cat. no. sc 220). Sections were
dewaxed, rehydrated, and treated with 0.05% Saponin in water for 30 min
at room temperature. Saponin was removed by washing three times for 5
min each in TBS with 0.1% Tween 20 at room temperature. Immunostain-
ing was then performed using components and directions from the
Vectastain Elite staining kit; however, Cy3-conjugated avidin (Vector
Laboratories) was substituted for the avidin-biotin-peroxidase complex.
Excess Cy3-conjugated avidin was removed from the sections by washing
three times for 10 min each in TBS with 0.1% Tween 20 at room tempera-
ture, and the sections were immediately mounted with Aquapoly mount
(Poly Sciences). Fluorescence was observed and imaged using a Zeiss Ax-
iophot microscope and a Princeton Instruments CCD camera with Sello-
mics imaging software.
 
In Situ Hybridization
 
In situ hybridization was performed as described (Pelton et al., 1990b).
Metatarsal rudiments were fixed overnight in paraformaldehyde at 4
 
8
 
C,
then decalcified in 1 mM Tris, pH 7.5, 10% EDTA tetrasodium salt, 7.5%
polyvinyl pyrolidone, and 1 
 
m
 
l/ml DEPC at 4
 
8
 
C for 2 h to overnight. The
metatarsals were then dehydrated in alcohol and embedded in paraffin.
Sections (5 
 
m
 
m) were hybridized to 
 
35
 
S-labeled antisense riboprobes. The
 
Ihh
 
 plasmid (a kind gift from Andy McMahon, Harvard University, Cam-
bridge, MA) was linearized with XbaI, and riboprobe was synthesized us-
ing T7 polymerase. The 
 
PTHrP
 
 plasmid (a generous gift from Henry Kro-
nenberg, Harvard Medical School, Boston, MA) was linearized with
EcoRI, and riboprobe was synthesized using T3 polymerase. Slides were
exposed to photographic emulsion at 4
 
8
 
C for 2 wk, then developed, fixed,
and cleared. Sections were counterstained with 0.02% toluidine blue.
Bright field and dark field images were captured with a Princeton Instru-
ments CCD camera. Bright field and dark field images were merged using
the electronic photography imaging program from Sellomics.
 
Reverse Transcription PCR Analysis
 
RNA was extracted from cartilage rudiment cultures by lysis in guanidine
thiocyanate using the Ambion RNaqueous kit (cat. no. 1912) and the
manufacturer’s instructions with the modification that the cartilage rudi-
ments were first homogenized in the guanidine solution in a microcentri-
fuge tube with a small pestle. RNA was treated with RNase-free DNase
(Promega Corp.) for 1 h at 37
 
8
 
C, phenol/chloroform extracted, and etha-
nol precipitated. Precipitation of RNA was facilitated with 20 
 
m
 
g glycogen
per sample (Boehringer Mannheim). RNA concentration was determined
spectrophotometrically. For reverse transcription (RT)-PCR analysis,
cDNA was synthesized from 1 
 
m
 
g of total RNA as described in the Gene-
Amp RNA PCR kit (Perkin-Elmer) using the oligo dT primers. For each
sample, 5 
 
m
 
l cDNA was amplified with 0.2 
 
m
 
M primers and 0.2 mM nucle-
otides for 20 cycles. These conditions were determined to fall within the
length of area stained for type X collagen
length of total bone rudiment
--------------------------------------------------------------------------------------------------- 100 ´
% of total cartilage containing type X collagen. =
 
linear range of PCR product formation for both PTHrP and glyceralde-
hyde-6-phosphate dehydrogenase (GAPDH). Samples incubated without
reverse transcriptase were used to determine if there was DNA contami-
nation in the RNA samples. DNA contamination was not detected in the
RNA from the three separate experiments performed. PCR products
were blotted to nylon membrane as described (Southern, 1975) and
probed with 
 
32
 
P-labeled cDNA probes for PTHrP (obtained from H. Kro-
nenberg, Harvard Medical School, Boston, MA) and GAPDH. GAPDH
was used as an internal control for the amount of cDNA used in each reac-
tion. Relative levels of mRNA were quantified using a Molecular Dynam-
ics PhosphorImager. GAPDH primers were purchased from Clontech.
The PTHrP primers used were as follows (Suda et al., 1996): PTHrP5
 
9
 
,
TGG TGT TCC TGC TCA GCT A, and PTHrP3
 
9
 
, CCT CGT CGT CTG
ACC CAA A.
 
Results
 
TGF-
 
b
 
1 Alters Development of Embryonic Metatarsal 
Rudiments Grown in Organ Culture
 
Previously, we showed that expression of a dominant-neg-
ative mutation of the TGF-
 
b
 
 type II receptor in skeletal
tissue in transgenic mice resulted in increased hyper-
trophic differentiation (Serra et al., 1997), suggesting that
TGF-
 
b
 
 regulates terminal differentiation in vivo. To deter-
mine the effects of exogenously added TGF-
 
b
 
1 on endo-
chondral bone development, mouse metatarsal rudiments
isolated from embryos at 15.5 d of gestation and grown in
a chemically defined medium (Dieudonne et al., 1994)
were used in the following experiments (Fig. 1). Organ
culture allows for the study of complex biological pro-
cesses in a three-dimensional structure in the context of
native cell–cell and cell–extracellular matrix interactions.
Over 5 d, cartilage organ cultures grew longitudinally and
several stages of endochondral bone formation were de-
tected (Fig. 1, a–d). The zone of hypertrophic cartilage
(clear area plus dark area in the center of the rudiment),
calcified zone (dark area), and proximal and distal bone
ends representing resting and proliferating zones of carti-
lage have been described previously (Dieudonne et al.,
1994; and see Fig. 1 d and Fig. 2 A). Treatment with 1 ng/
ml TGF-
 
b
 
1 (data not shown) and 10 ng/ml TGF-
 
b
 
1 (Fig. 1
e) for 5 d inhibited longitudinal growth of the cartilage ru-
Figure 1. Embryonic mouse metatarsal bone rudiments grown in
organ culture. Mouse metatarsals were isolated at 15.5 d p.c. (a)
and placed in a chemically defined medium. By 1 (b) and 3 d in
culture (c), the explants had grown longitudinally and a clear
area of hypertrophic cartilage was observed in the center of the
bone rudiments. After 5 d in culture (d), matrix mineralization
was observed in the center of the explants. Treatment with 10 ng/ml
TGF-b1 (e) inhibited longitudinal growth and matrix mineraliza-
tion. 
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diment (Fig. 1, d and e; control length 
 
5 
 
3.5 
 
6
 
 0.12 mm,
 
n 
 
5 
 
4; 10 ng/ml TGF-
 
b
 
1 
 
5 
 
2.46 
 
6
 
 0.12 mm,
 
 n 
 
5 
 
3). In
addition, mineralized matrix was not detected in TGF-
 
b
 
1–treated cultures (compare Fig. 1, d and e).
To further characterize the effects of TGF-
 
b
 
1 on bone
development, the histology of untreated and TGF-
 
b
 
1–
treated cartilage rudiments was examined. In untreated
cartilage rudiments grown in culture for 5 d, histologically
defined resting, proliferating, and hypertrophic zones
were clearly demarcated in hematoxylin and eosin–stained
sections (Fig. 2 A). These zones of cartilage were not eas-
ily recognized in cultures treated with 10 ng/ml TGF-
 
b
 
1,
and treatment appeared to result in a decreased fraction of
histologically hypertrophic cartilage (Fig. 2 B). In addi-
tion, the perichondrium in TGF-
 
b
 
1–treated cultures con-
tained up to eight layers of cells, while the perichondrium
in control cultures was only two to three cell layers thick
(Fig. 2, A and B). The morphology and histology of TGF-
 
b
 
1–treated metatarsal bone rudiments suggested that
TGF-
 
b
 
 could have effects on both cell proliferation and
differentiation.
The effect of TGF-
 
b
 
1 on bone length could be in part
Figure 2. Metatarsal bone ru-
diment histology. Sections
from embryonic metatarsal ru-
diments untreated (A) or
treated with 10 ng/ml TGF-b1
(B) for 5 d were stained with
hematoxylin and eosin. Zones
of histologically defined rest-
ing (RZ), proliferating (PZ),
and hypertrophic (HZ) carti-
lage were easily detected in
sections from untreated cul-
tures (A). Cartilage zones
were not clearly demarcated in
the TGF-b1–treated cultures,
and the perichondrium (ar-
rowhead) was thicker relative
to the untreated controls (B).
BrdU incorporation. Metatar-
sals in organ culture that were
either untreated (C) or treated
(D) with 10 ng/ml TGF-b1 for
24 h were labeled with BrdU
for an additional 2.5 h. BrdU
incorporation was detected us-
ing immunofluorescence. La-
beled cells were detected
throughout the prehypertro-
phic cartilage in untreated cul-
tures (C). Labeled cells were
not detected in the cartilage
of TGF-b1–treated metatarsal
cultures; however, many cells
were labeled throughout
the perichondrium (D). Dif-
ferentiation markers. Type X
collagen, a marker of hyper-
trophic cartilage, was immu-
nolocalized to the histologi-
cally hypertrophic cartilage in
untreated (E) and TGF-b1–
treated (F) cultures. The frac-
tion of cartilage that stained
for type X collagen was re-
duced in TGF-b1–treated cul-
tures (F) relative to the un-
treated control (E). No
staining was detected in the
absence of primary antibody
(data not shown). Ihh mRNA,
a marker for cells committed to become hypertrophic, was localized by in situ hybridization to sections from control (G) and TGF-b1–
treated (H) metatarsal cultures. In untreated rudiments, Ihh mRNA was localized to a population of flat cells closest to the zone of hy-
pertrophy, and expression continued into the hypertrophic layer (G). Ihh mRNA was localized to a very small population of cells in the
center of the TGF-b1–treated cultures (H). 
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due to effects on cell proliferation. To test this hypothesis,
bone rudiments were either treated with the TGF-
 
b
 
1 vehi-
cle or were treated with 10 ng/ml TGF-b1 for 24 h fol-
lowed by treatment with BrdU for 2.5 h. BrdU incorpora-
tion was assayed using immunofluorescence (Fig. 2, C and
D). In control cultures, BrdU-labeled cells were detected
throughout the histologically defined zones of resting and
proliferating cartilage (Fig. 2 C). Cell proliferation in the
histologically defined resting zone is not unusual in fetal
bones. Treatment with TGF-b1 dramatically inhibited
chondrocyte proliferation as measured by the lack of
BrdU-labeled cells in the cartilage (Fig. 2 D), suggesting
that inhibition of chondrocyte growth participates in the
decrease in bone length observed after treatment with
TGF-b1. In contrast, TGF-b1–treated rudiments had an
increase in the number of BrdU-labeled cells in the peri-
chondrium compared with the untreated cultures (Fig. 2,
C and D), suggesting that TGF-b1 stimulated growth of
perichondrial cells.
Immunolocalization of type X collagen was used to de-
termine the effects of TGF-b1 on hypertrophic differentia-
tion in the organ culture model. Type X collagen is a well-
documented marker for hypertrophic cartilage (Schmid
and Linsenmayer, 1987). Expression of Ihh, a marker for
cells committed to become hypertrophic (Bitgood and Mc-
Mahon, 1995; Vortkamp et al., 1996), was also used to de-
termine the effects of TGF-b1 on hypertrophic differentia-
tion. In untreated metatarsal rudiments grown in culture
for 5 d, the matrix of the histologically hypertrophic carti-
lage contained type X collagen (Fig. 2 E). Ihh expression
was localized to prehypertrophic chondrocytes in the
lower zone of proliferation (transition cells) and continued
into the zone of hypertrophy (Fig. 2 G). Treatment with
TGF-b1 resulted in a decrease in the amount of histologi-
cally hypertrophic cartilage as well as a decrease in the
fraction of the cartilage area stained for type X collagen
(Fig. 2, E and F; control 5 30 6 3.7%, n 5 11; TGF-b1 5
19.3 6 3.9%, n 5 10). This measurement takes into ac-
count changes in the total length of the bone rudiment and
suggests that inhibition of hypertrophic differentiation oc-
curs independent of the inhibition in longitudinal growth.
Ihh mRNA was restricted to a small population of cells in
the center of the TGF-b1–treated rudiment (Fig. 2 H),
suggesting that treatment with TGF-b1 resulted in a de-
crease in the number of cells committed to hypertrophic
differentiation in the metatarsal organ cultures. The data
taken together suggest that TGF-b1 acts to inhibit several
points of endochondral bone formation, including cell
growth, hypertrophic differentiation, and matrix mineral-
ization.
Embryonic Metatarsal Rudiments in Organ Culture 
Express the TGF-b Type I and Type II Receptors
TGF-bs signal through heteromeric serine/threonine ki-
nase receptors (reviewed in Derynck, 1994; Massague et al.,
1994; Ten Dijke et al., 1996; Alevizopoulos and Mermod,
1997). Both type I and type II receptors are required to
generate a response to TGF-b (Laiho et al., 1990; Wrana
et al., 1992; Ruberte et al., 1995). The current model is that
TGF-b ligand binds to the TGF-b type II receptor on the
cell surface (Wrana et al., 1994). The type II receptor is
then able to recruit the type I receptor to form a heterotet-
rameric complex of two type I and two type II receptors.
The type II receptor, which is a constitutively active ki-
nase, phosphorylates the type I receptor, activating the
type I serine/threonine kinase. Downstream targets of the
type I receptor then transduce the signal to the nucleus. To
determine which cell types in the cartilage rudiment cul-
tures potentially respond to the TGF-b1 signal, expression
of the TGF-b type I and type II receptors in embryonic
mouse metatarsal rudiments isolated at 15.5 d of gestation
and kept in culture for 24 h (data not shown) or 5 d (Fig. 3)
was examined by immunofluorescence. The receptor ex-
pression pattern was similar at 24 h and 5 d of culture.
Staining for the TGF-b type II receptor was detected at
varying levels in all the cell types in the cartilage rudiment
(Fig. 3). The highest levels of staining were detected in the
perichondrium, the resting cartilage at the most distal ends
of the metatarsal, the cells in the portion of proliferating
zone closest to the hypertrophic zone (transition zone),
and hypertrophic cells in the center of the rudiment.
Strong staining was also observed in small round cells
within the osteoid seam between the zone of hypertrophy
and the perichondrium/periosteum. These cells are pre-
sumably osteoblasts. Immunofluorescent staining with an
antibody directed to the TGF-b type I receptor demon-
strated an expression pattern for the type I receptor simi-
lar to that observed for the type II receptor (Fig. 3). The
pattern of expression for the receptor proteins suggests
that all cells are potentially capable of responding to TGF-
b1, but also suggests that cells in the perichondrium, distal
tips of the rudiment, lower proliferating, and hypertrophic
zones could be more sensitive to treatment with TGF-b1.
Treatment with TGF-b1 Stimulates Expression of 
PTHrP mRNA, and PTHrP Inhibits
Hypertrophic Differentiation
To provide evidence for the model that TGF-b and
PTHrP act in a common signal cascade to regulate the rate
of chondrocyte differentiation, the hypothesis that TGF-b1
regulates expression of PTHrP mRNA in metatarsal cul-
tures was tested. RNA extracted from cartilage rudiments
either untreated or treated with 10 ng/ml TGF-b1 for 8 h
or 5 d was analyzed using RT-PCR analysis (Fig. 4, A and
B). Conditions were determined such that PCR product
formation would be in the linear range. PTHrP mRNA
levels were normalized to the expression of GAPDH, a
constitutively active housekeeping gene. In three separate
experiments, treatment with TGF-b1 resulted in an ap-
proximately threefold increase in PTHrP mRNA levels af-
ter 8 h, and the increased levels of PTHrP mRNA per-
sisted for up to 5 d of treatment (Fig. 4 B). In situ
hybridization was used to localize expression of PTHrP
in cartilage rudiments untreated or treated with TGF-b1
for 6 h or 5 d (Fig. 4 C). PTHrP mRNA was localized to
the periarticular region in both untreated and TGF-b1–
treated cultures at 6 h and 5 d (Fig. 4 C). Cultures treated
with TGF-b1 also demonstrated ectopic PTHrP mRNA
expression in the perichondrium (Fig. 4 C). These data
support the model that TGF-b1 acts to positively regulate
PTHrP expression.
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we would predict that PTHrP would have some of the
same effects as TGF-b1 on bone development. Previously,
it was shown that transgenic mice that misexpress PTHrP
from the type II collagen promoter and mice that express a
constitutively active PTH/PTHrP receptor show a delay in
hypertrophic differentiation (Weir et al., 1996; Amling et
al., 1997; Schipani et al., 1997). The hypothesis that PTHrP
inhibits development of metatarsal rudiments grown in or-
gan culture was tested, and the effects of PTHrP were
compared with those of TGF-b1 (Figs. 5 and 6). Similar to
treatment with TGF-b1 (Fig. 5 e), treatment with as little
as 1028 M PTHrP inhibited mineralization of the cartilage
matrix in the explant cultures (Fig. 5 b) relative to the un-
treated control (Fig. 5 a). In contrast to TGF-b1, PTHrP at
a concentration as high as 1025 M did not result in signifi-
cant inhibition of longitudinal growth in the explants when
compared with the untreated cultures (Fig. 5, a, d, and e;
control length 5 3.64 6 0.16 mm, n 5 5; PTHrP 5 3.86 6
0.3 mm, n 5 3; TGF-b1 5 2.52 6 0.22 mm, n 5 5). The hy-
pothesis that PTHrP did not affect chondrocyte prolifera-
tion was confirmed using the BrdU incorporation assay
(Fig. 6, D and E). Cultures were untreated or treated with
1026 M PTHrP for 24 h followed by treatment with BrdU
for an additional 2.5 h. BrdU was detected using immuno-
fluorescence. There were no detectable differences in
BrdU labeling in control (Fig. 6 D) and PTHrP-treated
(Fig. 6 E) cultures. The effects of PTHrP on metatarsal or-
gan cultures were further characterized by staining with
hematoxylin and eosin (Fig. 6, A–C) and immunostaining
for type X collagen (data not shown). Histological exami-
nation of organ cultures revealed a decrease, relative to
the untreated control (Fig. 6 A), in the fraction of the car-
tilage area that contained histologically hypertrophic carti-
lage and stained with type X collagen in both PTHrP- (Fig.
6 B) and TGF-b1– (Fig. 6 C) treated cultures (control 5 30 6
3.7%, n 5 11; TGF-b1 5 19.3 6 3.9%, n 5 10; PTHrP 5
16.7 6 3.2%, n 5 3). The histology and BrdU labeling of
perichondrium were not affected by PTHrP (Fig. 6, B and
E). These data indicate that PTHrP and TGF-b have some
distinct and some overlapping functions. Both PTHrP and
TGF-b1 inhibit hypertrophic differentiation and matrix
mineralization in the assays described above; however, in
contrast to TGF-b1, PTHrP did not affect longitudinal
growth, chondrocyte proliferation, or the perichondrium.
A model whereby TGF-b could act through PTHrP to reg-
ulate hypertrophic differentiation and/or matrix mineral-
ization is suggested.
TGF-b1 Has PTHrP-dependent and
PTHrP-independent Effects on the Development
of Embryonic Metatarsal Rudiments Grown in
Organ Culture
Metatarsal organ cultures from embryos with targeted de-
letion of the PTHrP gene (Karaplis et al., 1994) were used
to test the hypothesis that PTHrP is required for TGF-
b–mediated effects on endochondral bone development.
Two separate experiments were performed to compare
the effects of 0 (Fig. 7, A and D), 1 (Fig. 7, B and E), and
10 ng/ml TGF-b1 (Fig. 7, C and F) on rudiments from
PTHrP-positive (1/1 or 1/2; Fig. 7, A–C) and PTHrP-
null (2/2; Fig. 7, D–F) embryos. There were no detect-
Figure 3. Immunofluorescent
localization of TGF-b type I
and type II receptors. TGF-b
type II (A and C) and type I
(B and D) receptor proteins
were localized by immuno-
fluorescence in sections of
metatarsal bone rudiments
grown in culture for 5 d.
Staining was observed in all
cells in the metatarsal ex-
plants but was detected at
higher levels in the perichon-
drium (white arrow, C and
D), in flat cells in the lower
portion of the zone of prolif-
eration (dashed arrows, A
and B), and in resting chon-
drocytes at the most distal
tips of the metatarsal (A).
Round cells, presumably os-
teoblasts, located between
the perichondrium and zone
of hypertrophy were also
stained for both type I and
type II receptors (arrow-
heads, C and D). Bar: (A and
B) 100 microns; (C and D) 18
microns. No staining was de-
tected in the absence of pri-
mary antibody (data not
shown).Serra et al. TGF-b and PTHrP in Skeletal Development 789
able differences in cartilage rudiments from PTHrP-posi-
tive and PTHrP-null cultures at the time of dissection
(15.5 d p.c.) or at the time TGF-b was added (16 h after
dissection; data not shown). By 5 d of culture, rudiments
from mice homozygous for the PTHrP deletion demon-
strated increased matrix mineralization relative to PTHrP-
positive controls (Fig. 7, A and D). This observation is
consistent with the reported phenotype of PTHrP-null
mice (Karaplis et al., 1994; Amizuka et al., 1994, 1996).
PTHrP-positive cultures treated with TGF-b1 for 5 d dem-
onstrated a dose-dependent decrease in length and miner-
alized matrix (Fig. 7, A–C; Table I). Cultures from
PTHrP-null embryos demonstrated similar effects (Fig. 7,
D–F; Table I), suggesting that PTHrP is not required for
TGF-b1–mediated effects on growth or matrix mineraliza-
tion. The effects on longitudinal growth were predicted in
the previous experiment where addition of PTHrP to ex-
plant cultures did not alter growth.
To determine if PTHrP is required for the effects of
TGF-b1 on metatarsal histology, hematoxylin and eosin–
stained sections of organ cultures from PTHrP-positive
(Fig. 8, A–C) and PTHrP-null embryos (Fig. 8, D–F) ei-
ther untreated or treated with TGF-b1 were examined.
Consistent with the assertion that PTHrP normally in-
hibits hypertrophic differentiation (Karaplis et al., 1994;
Amizuka et al., 1994, 1996), all of the chondrocytes in un-
treated PTHrP-null rudiments were histologically hyper-
trophic (Fig. 8 D), whereas only a fraction of the cartilage
in PTHrP-positive cultures is hypertrophic (Fig. 8 A). In
PTHrP-positive cultures, TGF-b1 treatment resulted in a
dose-dependent decrease in the fraction of chondrocytes
in the histologically hypertrophic and proliferating zones
(Fig. 8, A–C). In contrast, most of the chondrocytes in ru-
diments from PTHrP-null mice remained histologically
hypertrophic despite treatment with 1 or 10 ng/ml TGF-b1
Figure 4. PTHrP mRNA ex-
pression. (A) Metatarsal or-
gan cultures were grown in
the absence (2) or presence
(1) or 10 ng/ml TGF-b1, and
RNA was extracted after 8 h
or 5 d of treatment. RNA
was used in RT-PCR assays
to determine PTHrP mRNA
expression levels. PCR was
performed under conditions
determined to be in the lin-
ear range of product forma-
tion. PCR fragments were
blotted to nylon membranes
and hybridized to 32P-labeled
PTHrP and GAPDH probes.
(B) PTHrP levels were quan-
tified using a Molecular
Dynamics PhosphorImager.
PTHrP expression was nor-
malized to expression of
GAPDH, a constitutive house-
keeping gene. Data are
shown as the fold induction
relative to the untreated con-
trol in three separate experi-
ments. N.D., not determined.
(C) PTHrP mRNA was lo-
calized by in situ hybridiza-
tion to sections from metatarsals either untreated (0b) or treated (1b) with 10 ng/ml TGF-b1 for 6 h or 5 d. In untreated cultures,
PTHrP was localized to the periarticular region (arrow). TGF-b1–treated cultures demonstrated that PTHrP mRNA localized to the
perichondrium (arrow) as well as to the periarticular region.
Figure 5. Effects of PTHrP on metatarsal bone rudiments grown
in organ culture. Metatarsal explants were either untreated (a) or
treated with 1028 (b), 1027 (c), or 1025 M (d) PTHrP, or with 10
ng/ml TGF-b1 for 5 d (e). Matrix mineralization was inhibited at
all concentrations of PTHrP. Longitudinal growth was not af-
fected by treatment with PTHrP.The Journal of Cell Biology, Volume 145, 1999 790
(Fig. 8, D–F). Treatment with 1 (Fig. 8, B and E) and 10
ng/ml TGF-b1 (Fig. 8, C and F) resulted in an increase in
the thickness of the perichondrium relative to control cul-
tures (Fig. 8, A and D) in both PTHrP-positive and
PTHrP-null cultures. The data suggest PTHrP is not re-
quired for the effects of TGF-b on the perichondrium but
indicate that PTHrP may be required for TGF-b–medi-
ated effects on hypertrophic differentiation. To specifi-
cally determine the role of PTHrP in TGF-b–mediated
effects on hypertrophic differentiation, sections from
PTHrP-positive and PTHrP-null organ cultures untreated
or treated with TGF-b1 were immunostained for type X
collagen, a marker of hypertrophic differentiation (Fig. 9).
Treatment of PTHrP-positive cultures with 1 ng (Fig. 9 B)
and 10 ng/ml TGF-b1 (Fig. 9 C) resulted in a decrease in
the fraction of cartilage stained for type X collagen rela-
tive to untreated cultures (Fig. 9 A). In contrast, TGF-b1
had no effect on the fraction of cartilage stained for type X
collagen in PTHrP-null cultures (Fig. 9, D–F). Since treat-
ment with TGF-b1 did not inhibit hypertrophic differenti-
ation in PTHrP-null cultures, the data indicate that PTHrP
is required for the effects of TGF-b1 on hypertrophic dif-
ferentiation and suggest TGF-b acts upstream of PTHrP
in a common signaling cascade to regulate differentiation.
The data also suggest that TGF-b1 has both PTHrP-
dependent and PTHrP-independent effects on endochon-
dral bone formation.
Discussion
Embryonic metatarsal bone rudiments grown in organ cul-
ture were used to test the hypothesis that TGF-b1 acts up-
stream of PTHrP to regulate chondrocyte differentiation.
TGF-b1 acted at several check points during endochon-
dral bone formation, inhibiting longitudinal growth, hyper-
trophic differentiation, and matrix mineralization. TGF-b
drastically reduced BrdU labeling in chondrocytes of the
histologically defined resting/proliferating zone by 24 h
of treatment, suggesting that TGF-b affects longitudinal
growth by regulating chondrocyte proliferation. However,
additional effects of TGF-b on apoptosis or extracellular
matrix production cannot be ruled out by the experiments
presented here. PTHrP also inhibited chondrocyte hyper-
trophy and matrix mineralization but did not affect cell
proliferation. TGF-b1 stimulated expression of PTHrP
mRNA, suggesting that TGF-b1 and PTHrP could be part
Figure 6. Effects of PTHrP on metatarsal histology. Hematoxy-
lin and eosin–stained sections of metatarsal bone rudiments
grown in the absence of growth factors (A) or in the presence
of 1025 M PTHrP (B) or 10 ng/ml TGF-b1 (C) are shown.
PTHrP (B) and TGF-b1 (C) treated rudiments demonstrate a
smaller zone of hypertrophy (HZ) relative to the untreated
control (A). Cells that were not hypertrophic (arrow) were
scattered throughout the zone of hypertrophy in both PTHrP
(B) and TGF-b1 (C) treated cultures. PTHrP-treated rudi-
ments (B) had an extended histologically defined zone of prolif-
eration (PZ) and resting cartilage (RZ), whereas TGF-b1–
treated cultures (C) demonstrated a decrease in the length of
the zone of proliferation. Thickened perichondrium was ob-
served in the TGF-b1–treated explants (arrowhead, C) but not in the PTHrP-treated explants (B). BrdU labeling. Metatarsals either
untreated (D) or treated with 1025 M PTHrP (E) for 24 h were labeled with BrdU for an additional 2.5 h. BrdU incorporation was de-
tected using immunofluorescence. There were no detectable differences in labeled cells in PTHrP-treated (E) and control (D) cultures.Serra et al. TGF-b and PTHrP in Skeletal Development 791
of the same signaling cascade to regulate hypertrophic dif-
ferentiation and/or matrix mineralization. The hypothesis
that PTHrP is required for TGF-b1–mediated effects on
endochondral bone formation was tested using organ cul-
tures from PTHrP-null mice. TGF-b1 did not inhibit hy-
pertrophic differentiation in PTHrP-null cultures, suggest-
ing that inhibition of hypertrophic differentiation occurred
through a PTHrP-dependent mechanism. In contrast, lon-
gitudinal growth and matrix mineralization were inhibited
by TGF-b1 in both PTHrP-expressing and PTHrP-null
cultures, suggesting TGF-b has PTHrP-independent ef-
fects as well.
A model where longitudinal growth, hypertrophic dif-
ferentiation, and matrix mineralization can be regulated
independently is supported by data presented here and by
others (Dieudonne et al., 1994; Long and Linsenmayer,
1998). Inhibition of hypertrophic differentiation by TGF-b1
is not solely a consequence of reduced proliferation.
Treatment with TGF-b resulted in a decrease in the frac-
tion of the bone area that stained for type X collagen. This
measurement took into account differences in the total
length of the bone rudiment and suggest that TGF-b in-
hibits hypertrophic differentiation in addition to inhibiting
longitudinal growth. TGF-b was previously shown to be
sufficient to inhibit hypertrophic differentiation in chon-
drocyte cultures (Kato et al., 1988; Ballock et al., 1993;
Tschan et al., 1993; Bohme et al., 1995; Dieudonne et al.,
1994). In addition, expression of a dominant-negative
form of the TGF-b type II receptor in transgenic mice re-
sulted in increased hypertrophic differentiation (Serra et
al., 1997), suggesting that TGF-b is necessary to prevent
hypertrophy in vivo. Likewise, inhibition of matrix miner-
alization by TGF-b1 is most likely not a consequence of
reduced hypertrophic differentiation. Previously, it was
shown that treatment with TGF-b1 resulted in only a 40%
inhibition in hypertrophy but a complete inhibition of ma-
trix mineralization, suggesting that TGF-b inhibited ma-
trix mineralization independently of cellular differentia-
tion (Dieudonne et al., 1994). In the present report, we
demonstrate that TGF-b1 completely inhibited matrix
mineralization in the absence of PTHrP even though these
cultures were completely hypertrophic.
Immunolocalization of TGF-b type I and type II recep-
tors suggests that all cells in the cartilage rudiment are po-
tentially able to respond to TGF-b1; however, the data
also suggest that some cell types may be more sensitive to
treatment. High levels of receptor protein were localized
to perichondrial cells, a subset of resting chondrocytes at
the ends of the skeletal element, cells in the proliferating
zone closest to the hypertrophic zone, and the hyper-
trophic cells in the center of the long bone rudiment. High
levels of the TGF-b receptors in the perichondrium sug-
gest that these cells are able to respond to TGF-b directly.
Treatment with TGF-b was shown to increase the number
of BrdU-labeled cells in the perichondrium, and TGF-b1
was able to stimulate perichondrial growth in the absence
of PTHrP. Localization of the TGF-b receptors in chon-
drocytes suggests that TGF-b could act directly on chon-
drocytes to regulate growth or hypertrophic differentia-
tion; alternatively, TGF-b1 could act indirectly through
the perichondrium. Recently it was demonstrated that
growth and differentiation of long bone cartilage are me-
diated by factors from the perichondrium (Long and Lin-
senmayer, 1998). Removal of the perichondrium from
chick long bone rudiments resulted in an increase in the
length of the explants, an increase in DNA synthesis in the
zone of proliferation, and increased hypertrophic differen-
tiation (Long and Linsenmayer, 1998). Long growth con-
tinued in the perichondrium-free chick cultures in the
presence of exogenously added PTHrP even though hy-
pertrophic differentiation was inhibited (Long and Linsen-
mayer, 1998). This is in agreement with our results in
mouse metatarsal organ cultures where PTHrP inhibited
hypertrophic differentiation but did not affect incorpora-
tion of BrdU. In addition, we observed that inhibition of
longitudinal growth by TGF-b1 occurred independently of
PTHrP, suggesting that, if the effect of TGF-b1 on growth
Table I. Metatarsal Bone Rudiment Length
0 ng TGF-b1 1 ng TGF-b1 10 ng TGF-b1
PTHrP1 3.44 6 0.16 mm 2.72 6 0.10 mm 2.14 6 0.16 mm
n 5 13 n 5 8 n 5 6
PTHrP2 3.14 6 0.13 mm 2.56 6 0.22 mm 2.20 6 0.22 mm
n 5 11 n 5 5 n 5 6
Figure 7. Effects of TGF-b1
on metatarsal explants from
PTHrP-null mice. Metatar-
sal bone rudiments from
PTHrP-positive (A–C) and
PTHrP-null (D–F) mice were
left untreated (A and D) or
were treated with 1 (B and
E) or 10 ng/ml TGF-b1 (C
and F) for 5 d. Treatment
with TGF-b1 resulted in
decreased length and ma-
trix mineralization in both
PTHrP-positive and PTHrP-
null cultures. Representative
explants from one of the two
separate experiments are
shown.The Journal of Cell Biology, Volume 145, 1999 792
is mediated through the perichondrium, another factor is
involved. Fibroblast growth factor receptor 3 (FGFR3) is
expressed in chondrocytes in the proliferating zone (Pe-
ters et al., 1993; Deng et al., 1996), and FGFR3-null mice
demonstrate enhanced and prolonged longitudinal bone
growth (Deng et al., 1996; Colvin et al., 1996). The ligand
for the FGFR3 that regulates endochondral bone forma-
tion is not known. TGF-b may modulate the expression or
activity of FGFs from the perichondrium and thereby indi-
rectly regulate longitudinal growth.
This suggests that TGF-b1 mediates hypertrophic differ-
entiation indirectly through PTHrP which is most likely
secreted from the perichondrium. TGF-b1 stimulated ex-
pression of PTHrP mRNA in the cartilage rudiment cul-
tures, and expression was localized to the perichondrium
and periarticular area. TGF-b1 has been shown to stimu-
late expression of PTHrP mRNA and protein in several
cultured cell types, including carcinoma cell lines, uterine
and ovarian epithelial cells, and articular chondrocytes
(Gillespie and Martin, 1994; Kiriyama et al., 1993; Merry-
man et al., 1994; Southby et al., 1996; Tsukazaki et al.,
1995). Additional support of an indirect effect of TGF-b
mediated through the perichondrium comes from trans-
genic mice that express a truncated, dominant-negative
TGF-b type II receptor in the perichondrium. These mice
demonstrate increased hypertrophic differentiation in the
growth plate and suggest that TGF-b signaling in the peri-
chondrium is required to regulate hypertrophy (Serra et al.,
1997).
Development of skeletal elements requires the coordi-
nation of signals from several sources. It was recently
shown that Ihh and PTHrP form a negative feedback loop
that provides a mechanism for chondrocytes to sense and
downregulate their rate of differentiation (Vortkamp et al.,
1996; Lanske et al., 1996; Wallis, 1996). Misexpression of
Ihh in chick limb cartilage rudiments resulted in inhibition
of chondrocyte differentiation and increased expression of
Ptc and Gli in the perichondrium, suggesting that the peri-
chondrium contained the Ihh responding cells (Vortkamp
et al., 1996). Misexpression of Ihh also resulted in in-
creased expression of PTHrP, and it was shown that
PTHrP was required for the inhibitory activities of Hh on
chondrocyte differentiation (Vortkamp et al., 1996; Lan-
ske et al., 1996). Expression of a dominant-negative form
of the TGF-b type II receptor in mouse perichondrium re-
sults in increased terminal chondrocyte differentiation and
increased and persistent expression of Ihh (Serra et al.,
1997). Since Ihh normally acts as a negative regulator of
differentiation, it was proposed that TGF-b signaling is re-
quired for Ihh-mediated inhibition of chondrocyte differ-
Figure 8. Effects of TGF-b1
on the histology of metatar-
sal explants from PTHrP-null
mice. Sections of metatarsals
from PTHrP-positive (A–C)
and PTHrP-null (D–F) mice
untreated (A and D) or
treated with 1 (B and E) or
10 ng/ml TGF-b1 (C and F)
were stained with hematoxy-
lin and eosin. Zones of his-
tologically defined hyper-
trophic (HZ), proliferating
(PZ), and resting (RZ) carti-
lage were clearly visible
in untreated cultures from
PTHrP-positive mice (A).
All of the cartilage in the un-
treated PTHrP-null cultures
appeared hypertrophic (B).
Treatment with TGF-b1 in-
hibited the fraction of histo-
logically hypertrophic carti-
lage in the PTHrP-positive
cultures (A–C) but not in the
PTHrP-null cultures (D–F).Serra et al. TGF-b and PTHrP in Skeletal Development 793
entiation. There is precedent for such a model. The Dro-
sophila protein, Dpp, a member of the TGF-b superfamily,
can act as a secondary signal downstream of Hh to regu-
late the patterning of the imaginal disks (Heberlein et al.,
1993; Ingham and Fietz, 1995), and BMP-2 and BMP-4 are
induced by sonic Hh in the chick limb and hind gut
(Laufer et al., 1994; Roberts et al., 1995). Furthermore,
Hh- and TGF-b–related genes are coexpressed at many
sites of cell–cell communication in the mouse embryo (Bit-
good and McMahon, 1995). The present study suggests
that TGF-b acts upstream of PTHrP to negatively regulate
chondrocyte differentiation; however, whether or not TGF-b
mediates the effects of Ihh on PTHrP has not yet been ad-
dressed. Future experiments will provide further evidence
of how signaling from several factors is coordinated to
build and maintain a functional skeletal system.
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